Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The foundation of maintenance therapy has been with lenalidomide. There is increasing evidence to support lenalidomide as the backbone of combination therapy in the maintenance setting.
On February 22, 2017, the U.S. Food and Drug Administration (FDA) granted approval for the use of lenalidomide as maintenance therapy after autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with multiple myeloma.
The [EMA authorizes](brain://QMGe2vnxWkWiArAahJp9a…